Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INR101 PET/CT for Pelvic Lymph Node Metastasis in Prostate Cancer (Phase III)
CTR20250775Phase 3Active
- Sponsor
- 云核医药
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of INR101 in prostate adenocarcinoma, sponsored by 云核医药. Started May 2025; status: active.
02
Drugs
INR101
03
Conditions
prostate adenocarcinoma
Beyond the preview
Go deeper on CTR20250775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250775.